
Captor Therapeutics ®
Pipeline
Target
Indications
Modality
Discovery
Preclinical*
IND Filing
Phase IA / IB
-
GSPT1, NEK7, SALL4Hepatocellular carcinoma, Lung cancer, NET tumoursMG
History of the project:
01 Discovery
completed02 Preclinical
pending03 IND Filing
soon04 Phase IA / IB
soon
-
NEK7Autoimmunity, CNS, Metabolism, OncologyMG
History of the project:
01 Discovery
completed02 Preclinical
pending03 IND Filing
soon04 Phase IA / IB
soon
-
MCL-1Liquid & solid tumoursBID
History of the project:
01 Discovery
completed02 Preclinical
pending03 IND Filing
soon04 Phase IA / IB
soon
-
PKCӨAutoimmunity, Oncology, Transplantation, MetabolismBID
History of the project:
01 Discovery
pending02 Preclinical
soon03 IND Filing
soon04 Phase IA / IB
soon
-
New target projectsAutoimmunity, CancerMG BID
History of the project:
01 Discovery
pending02 Preclinical
soon03 IND Filing
soon04 Phase IA / IB
soon
-
New E3 ligase degradersAutoimmunity, CancerMG BID
History of the project:
01 Discovery
pending02 Preclinical
soon03 IND Filing
soon04 Phase IA / IB
soon
*Preclinical stage include IND-enabling studies,
BID – Bi-functional Degrader; MG – Molecular Glue
Assumed stage at the end of 2025